Anti-Trastuzumab Polyclonal Antibody|抗曲妥珠单抗多克隆抗体(靶标：曲妥珠单抗（抗HER2单抗）)
- 货号：RB9TAY286014
- 价格：面议
- 点击：473
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Rabbit |
| 克隆性 | Polyclonal |
| 抗体亚型 | IgG |
| 纯化方式 | Purified by antigen affinity column. |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA |
| 特异性 | The product is specific for Trastuzumab. This antibody serves as an excellent positive control for Trastuzumab immunogenicity (ADA) assays. |
| 靶标 | Rabbit polyclonal to Herceptin. |
| 免疫原 | Trastuzumab |
| 储存缓冲液 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
| 稳定性和储存 | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| 产品使用说明 | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| 登录号 | CAS: 180288-69-1 |
| 背景信息 | Trastuzumab with the brand name Herceptin, is an FDA-approved drug for HER2-targeted therapy for breast cancer. It is a recombinant humanized monoclonal antibody (IgG1 kappa). Trastuzumab binds to HER2 receptor present on the surface of HER2-positive tumour cells and suppresses the cells growth and proliferation. • Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro., PMID:28919583 • Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies., PMID:19393584 • Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines., PMID:32102522 • Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells., PMID:16091755 • Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3)., PMID:19530101 • Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity., PMID:12632061 • IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831., PMID:28533226 • Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer., PMID:11410505 • Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study., PMID:22037080 • Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy., PMID:21255939 |
| 备注 | For research use only. |
相关产品: